trial

Effects of Varenicline on Plasticity in Schizophrenia

NCTId NCT01934023
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 24 (actual)
Sponsored by Centre for Addiction and Mental Health
Primary completion 2015-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
24 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Double
Start
2013-09
Primary completion
2015-08
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Varenicline

Sponsors

Centre for Addiction and Mental HealthLead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Collaborator

Investigators

1
Tony P George, M.D.Principal Investigator

Sites

1 total
Toronto, Canada

Linked catalysts

1
Effects of Varenicline on Plasticity in Schizophrenia — primary completion2015-08

Facts & assertions

4 sourced
Enrollment
24
Phase
PHASE2
Primary Completion Date
2015-08
Status
COMPLETED
relationships
The graph out of here
drug
Varenicline
drug
lead_sponsor
Centre for Addiction and Mental Health
company
collaborator
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Tony P George, M.D.
person